![Help 4 HD Live! artwork](https://is5-ssl.mzstatic.com/image/thumb/Podcasts123/v4/d7/6f/33/d76f33bd-de2e-5600-63bf-52295b1c801e/mza_3103069902989466564.jpg/100x100bb.jpg)
The HD View with First HD Crew
Help 4 HD Live!
English - November 12, 2013 23:30 - 41 minutes - 9.17 MB - ★★★★★ - 11 ratingsHealth & Fitness clinical trial education hd research neuropsychiatry neurology hd & jhd education Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Tuesday, November 12, 2013
Join us for an update on the HSG First-HD clinical trial with incredible special guests Jody Goldstein from Rochester and Greg Suter from the HNDC.
First-HD is a Phase III clinical research trial of an investigational drug called SD-809 Extended Release (ER) in persons who have a diagnosis of Huntington disease (HD). First-HD will look at how safe, tolerable and effective SD-809 ER is compared to placebo (inactive drug) in reducing chorea. First-HD will be enrolling participants across North America (United States and Canada) who have been diagnosed with HD and who have never taken tetrabenazine (Xenazine ®, Nitoman ®). Participants will be involved in this trial for approximately 4 months.
For more information about First-HD you can contact the HSG directly:
Toll-free number: (800) 487-7671 (North America)
OR
email: [email protected]
Visit: www.ClinicalTrials.gov